[Effect of diphenylhydantoin on the clinical manifestations and excretion of 5-hydroxyindoloacetic acid in Parkinson's disease].
D000328:Adult; D000368:Aged; D001921:Brain / Q000378:metabolism; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000652:urine*; D008875:Middle Aged; D009129:Muscle Tonus / Q000187:drug effects; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism / Q000652:urine; D010672:Phenytoin / Q000008:administration & dosage / Q000494:pharmacology*; D012701:Serotonin / Q000378:metabolism; D013997:Time Factors
D012701:Serotonin; D006897:Hydroxyindoleacetic Acid; D010672:Phenytoin
Wpływ dwufenylohydantony na obraz kliniczny i wydalanie kwasu 5-hydroksyindolooctowego w chorobie Parkinsona.